December 21, 2023
HIROTSU BIO SCIENCE INC.

HIROTSU Bioscience Inc.
New Director/CSO Appointed for Overseas Growth Strategy－ Welcomed Barret Comiskey, inventor of electronic ink and serial entrepreneur－

We as HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki
Hirotsu (Hereinafter referred to as “HIROTSU”) are pleased to announce that Barrett
Comiskey, a serial entrepreneur, and inventor of electronic ink used in products such as theAmazon Kindle, has been appointed as Director and Chief Strategy Officer (CSO) as ofDecember 21.
Up to this time, we have been conducting research and development to create a future in whichcancers can be detected at an early stage. With life expectancy continuing to increase around theworld, cancer has become an issue of international importance. N-NOSE®" is one of the few
technologies that can solve this problem because it is simple, highly accurate, and inexpensive.
Therefore, we have invited Barrett Comiskey to join our Board of Directors and CSO to expand NNOSE® beyond Japan and into the global market.
Barrett Comiskey invented electronic ink, the technology used in products such as the Amazon
Kindle, while studying at the Massachusetts Institute of Technology. This technology, for which hehas been awarded 75 patents, is considered one of the greatest innovations since letterpress
printing in the 15th century. Since then, the technology has evolved beyond books, with new
applications ranging from electronic shelf labels to outdoor signage. In addition to being an inventor,
he is also the co-founder of E Ink, the company based on the electronic ink technology, that has
since grown to a market capitalization of approximately $6 billion (about 0.9 trillion yen) in less than
10 years. Since then, he has established a wide range of experience and achievements by starting
businesses in different fields not only in the U.S. but also in China, Taiwan, and Southeast Asia.
Going forward, we will leverage his experiences and work together to implement the overseas
expansion of "N-NOSE"■Comment from Barrett Comiskey
Dr. Hirotsu's invention – reimagining a very common model biological organism to be a high-fidelity
biosensor that can solve one of the biggest social problems in the world - is an amazing exampleof thinking outside of fixed ideas which immediately resonated with me as a lifelong lateral-thinker.

The potential of an affordable, non-invasive, highly sensitive test that can detect “silent killercancers” at early stages is poised to change the face of cancer screening worldwide and savemillions of lives, avoiding the suffering of millions more.
When I met the team and felt their deep commitment to this important project, I felt a moral
imperative to support Dr.Hirotsu and his mission. This is why it is truly an honor to officially become
part of this team as its Chief Strategy Officer, to support Dr. Hirotsu in actualizing his vision in themost effective, efficient, and scalable way. HBS has already done an amazing job in Japan, and I
believe that with my experience in the US and a number of other countries, we
can successfully open the largest markets on the planet and accelerate Early Cancer Detection
worldwide.
■Career
He graduated from the Massachusetts Institute of Technology in 1997
with a B.S. in Mathematics. While in school, he invented electronic ink,
which is used in e-readers like Amazon Kindle. Based on thistechnology, he founded E Ink, Inc. a company that has since grown toa market capitalization of approximately $6 billion. In 2004, he earned
an MBA from Stanford Graduate School of Business. He wasrecognized as a Technology Pioneer by the World Economic Forum andwas the youngest inductee into the National Inventors Hall of Fame.
■About HIROTSU Bio Science
We as HIROTSU aim to protect the health and future security of people through research,development, and practical application of unique technology that utilize the capabilities of livingorganisms. Established in 2016, N-NOSE was put to practical use thanks to our researchers’
abundance of ideas and tireless efforts. Despite the importance of extending healthy life
expectancy being emphasized, it is said that one in every two people will be diagnosed withcancer in this age of 100-year life expectancy. We will contribute to solving these social issues
with the world's first groundbreaking technology that utilizes the power of nematodes, which havea superior sense of smell that no artificial device can match.
Company Name: HIROTSU Bio Science Inc.
Headquarters: New Otani Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo
Name of Representative: Takaaki Hirotsu, CEO
Date of Establishment: August 2016

Main Service: Research, development, and marketing of cancer screenings using nematode andnematode olfactory sensors
Corporate website: https://hbio.jp/en/■About “N-NOSE”
A primary cancer screening test that utilizes the highly accurate detection of cancer-specific odors
in human urine by the nematode C. elegans, which has an excellent sense of smell. By justsubmitting urine, it is a simple, inexpensive, highly accurate, and comprehensive systemic cancer
test. The test has been proven to detect 15 types of cancer: oral cavity pharynx cancer, esophagus
cancer, lung cancer, breast cancer, stomach cancer, liver cancer, pancreas cancer, gall bladdercancer, bile duct cancer, colon cancer, kidney cancer, bladder cancer, ovary cancer, uterus cancer,
prostate cancer, etc. Since its launch in January 2020, a total of over 500,000 people have beentested. The number of corporate customers has exceeded 1,700 (as of July 2023). From 2023, wealso launched "N-NOSE plus Pancreas" as a next-generation "cancer type specific test" of N-NOSE,
and "N-NOSE Dog" and "N-NOSE Cat" as cancer risk tests for pets.
Official service website : https://lp.n-nose.com/